These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
268 related articles for article (PubMed ID: 17393785)
1. [Experience of using three phosphodiesterase type 5 inhibitors in the same period for the treatment of erectile dysfunction]. Zhang SX; Gao P Zhonghua Nan Ke Xue; 2007 Mar; 13(3):226-8. PubMed ID: 17393785 [TBL] [Abstract][Full Text] [Related]
2. Erectile dysfunction: comparison of efficacy and side effects of the PDE-5 inhibitors sildenafil, vardenafil and tadalafil--review of the literature. Gresser U; Gleiter CH Eur J Med Res; 2002 Oct; 7(10):435-46. PubMed ID: 12435622 [TBL] [Abstract][Full Text] [Related]
3. Efficacy of PDE-5-inhibitors for erectile dysfunction. A comparative meta-analysis of fixed-dose regimen randomized controlled trials administering the International Index of Erectile Function in broad-spectrum populations. Berner MM; Kriston L; Harms A Int J Impot Res; 2006; 18(3):229-35. PubMed ID: 16239897 [TBL] [Abstract][Full Text] [Related]
4. [Comparison of efficacy and safety of phosphodiesterase type 5 inhibitors in the treatment of erectile dysfunction]. Chen Q; Wang N; Yao F; Lu X Zhonghua Nan Ke Xue; 2004 Apr; 10(4):302-4. PubMed ID: 15148932 [TBL] [Abstract][Full Text] [Related]
5. Patterns of switching phosphodiesterase type 5 inhibitors in the treatment of erectile dysfunction: results from the Erectile Dysfunction Observational Study. Hatzichristou D; Haro JM; Martin-Morales A; von Keitz A; Riley A; Bertsch J; Belger M; Wolka AM; Beardsworth A; Int J Clin Pract; 2007 Nov; 61(11):1850-62. PubMed ID: 17850306 [TBL] [Abstract][Full Text] [Related]
6. Therapeutic effectiveness and patient satisfaction after 6 months of treatment with tadalafil, sildenafil, and vardenafil: results from the erectile dysfunction observational study (EDOS). Martin-Morales A; Haro JM; Beardsworth A; Bertsch J; Kontodimas S; Eur Urol; 2007 Feb; 51(2):541-50; discussion 550. PubMed ID: 17084518 [TBL] [Abstract][Full Text] [Related]
7. Drug Insight: oral phosphodiesterase type 5 inhibitors for erectile dysfunction. Briganti A; Salonia A; Gallina A; Saccà A; Montorsi P; Rigatti P; Montorsi F Nat Clin Pract Urol; 2005 May; 2(5):239-47. PubMed ID: 16474835 [TBL] [Abstract][Full Text] [Related]
8. PDE5 inhibitors: are there differences? Carson CC Can J Urol; 2006 Feb; 13 Suppl 1():34-9. PubMed ID: 16526979 [TBL] [Abstract][Full Text] [Related]
9. Do vardenafil and tadalafil have advantages over sildenafil in the treatment of erectile dysfunction? Doggrell S Int J Impot Res; 2007; 19(3):281-95. PubMed ID: 17183346 [TBL] [Abstract][Full Text] [Related]
10. [Impact of the pharmacokinetic properties of PDE5 inhibitors on the dose/sexual intercourse interval]. Giuliano F; Vicaut E; Jeanpetit Y Prog Urol; 2008 Sep; 18(8):536-42. PubMed ID: 18760744 [TBL] [Abstract][Full Text] [Related]
11. Comparative relaxing effects of sildenafil, vardenafil, and tadalafil in human corpus cavernosum: contribution of endogenous nitric oxide release. Toque HA; Priviero FB; Teixeira CE; Claudino MA; Baracat JS; Fregonesi A; De Nucci G; Antunes E Urology; 2009 Jul; 74(1):216-21. PubMed ID: 19371941 [TBL] [Abstract][Full Text] [Related]
12. Comparison of phosphodiesterase type 5 (PDE5) inhibitors. Wright PJ Int J Clin Pract; 2006 Aug; 60(8):967-75. PubMed ID: 16780568 [TBL] [Abstract][Full Text] [Related]
13. Factors associated with preference for sildenafil citrate and tadalafil for treating erectile dysfunction in men naïve to phosphodiesterase 5 inhibitor therapy: post hoc analysis of data from a multicentre, randomized, open-label, crossover study. Eardley I; Montorsi F; Jackson G; Mirone V; Chan ML; Loughney K; Vail GM; Beardsworth A BJU Int; 2007 Jul; 100(1):122-9. PubMed ID: 17552960 [TBL] [Abstract][Full Text] [Related]
14. Patients' preference in the treatment of erectile dysfunction: a critical review of the literature. Morales AM; Casillas M; Turbi C Int J Impot Res; 2011; 23(1):1-8. PubMed ID: 21191396 [TBL] [Abstract][Full Text] [Related]
16. [Tadalafil for erectile dysfunction: outstanding efficacy for 36 hours]. Deng SM Zhonghua Nan Ke Xue; 2008 Sep; 14(9):857-60. PubMed ID: 18998474 [TBL] [Abstract][Full Text] [Related]
17. Phosphodiesterase 5 inhibitors in the management of benign prostatic hyperplasia and erectile dysfunction: the best of both worlds. Wong P; Lawrentschuk N; Bolton DM Curr Opin Urol; 2009 Jan; 19(1):7-12. PubMed ID: 19057210 [TBL] [Abstract][Full Text] [Related]
18. Phosphodiesterase-5 inhibitors for lower urinary tract symptoms in men. Gales BJ; Gales MA Ann Pharmacother; 2008 Jan; 42(1):111-5. PubMed ID: 18094344 [TBL] [Abstract][Full Text] [Related]
19. Prescribing all phosphodiesterase 5 inhibitors to a patient with erectile dysfunction--a realistic and feasible option in everyday clinical practice--outcomes of a simple treatment regime. Ströberg P; Hedelin H; Ljunggren C Eur Urol; 2006 May; 49(5):900-7; discussion 907. PubMed ID: 16564126 [TBL] [Abstract][Full Text] [Related]
20. The relationship between erectile dysfunction and cardiovascular disease. Part II: The role of PDE-5 inhibition in sexual dysfunction and cardiovascular disease. Kapur V; Chien CV; Fuess JE; Schwarz ER Rev Cardiovasc Med; 2008; 9(3):187-95. PubMed ID: 18953278 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]